NCT07465549 CART BP Pro-Guided Blood Pressure Management for Uncontrolled Hypertension
| NCT ID | NCT07465549 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Korea University Anam Hospital |
| Condition | Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2025-10-22 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2025-10-22 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This multicenter, prospective, open-label randomized trial compares CART BP Pro-guided blood pressure management with usual care based on office blood pressure in Korean adults with uncontrolled hypertension. The planned enrollment is 400 participants at three Korea University hospitals. Participants are assigned in a 1:1 ratio to the two groups. CART BP Pro is a ring-type device that estimates blood pressure from optical pulse signals. Both groups receive guideline-based antihypertensive care. The main outcome is the difference between groups in CART-derived, time-weighted 24-hour mean systolic blood pressure at the 24-week assessment, with an allowable assessment window of 16-32 weeks. Both groups undergo outcome assessment. Recording-quality rules allow some incomplete recordings, including early device return, while requiring sufficient duration and time coverage. Standardized office blood pressure, office blood pressure below 130/80 mmHg, other CART blood pressure measures, and adverse events are also assessed.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 19 years 2. Uncontrolled hypertension defined as office systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg 3. Ability and willingness to provide written informed consent and comply with study procedures Exclusion Criteria: 1. History of intolerance or contraindication to olmesartan, amlodipine, or hydrochlorothiazide 2. Suspected secondary hypertension 3. Atrial fibrillation 4. Pregnancy or lactation 5. Any serious medical condition that may interfere with study participation or interpretation of study results
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07465549 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07465549 currently recruiting?
Yes, NCT07465549 is actively recruiting participants. Contact the research team at drjoohj@korea.ac.kr for enrollment information.
Where is the NCT07465549 trial being conducted?
This trial is being conducted at Ansan, South Korea, Seoul, South Korea, Seoul, South Korea.
Who is sponsoring the NCT07465549 clinical trial?
NCT07465549 is sponsored by Korea University Anam Hospital. The trial plans to enroll 400 participants.